Connect Biopharma Holdings

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced topline results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002) for ulcerative colitis. CBP-307 0.2 mg demonstrated a numerical reduction for the primary endpoint of least squares mean change from baseline in.

Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study

SAN DIEGO, CA and TAICANG, China, May 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced top-line results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002), a once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC).

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

- Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline P ha se 2 CBP-307 Results in Mo d er a te-to- S evere Ulcerative Colitis Expected to Be Reported in H1 2022 - - C a sh B a l an c e o f RMB 1,706.9 million (U S D 267.7 milli o n) a t December 3 1 , 2 0 21 -

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

CMO appointment to propel Connect through clinical milestones across solid pipeline of inflammatory disease therapies in development

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

SAN DIEGO and TAICANG, China, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16, 2022 at 4:20 pm ET.

Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

—Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo

Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference

Key takeaways: Loss-making Connect Biopharma says Phase 3 clinical trials of its CBP-201 drug for atopic dermatitis will begin in second half of this year

Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares

—Phase 2b trial previously reported achievement of both primary and key secondary end points, demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo—

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

SAN DIEGO and TAICANG, China, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will host a conference call and webcast to review detailed data from its global Phase 2b trial of CBP-201 in adult patients with moderate-to-severe atopic dermatitis on Wednesday, January 5, 2022 beginning at 8:30 AM Eastern Time.

Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced the appointment of Mr. Steven Chan as Chief Financial Officer, effective November 22, 2021. Mr. Chan will report to Dr. Zheng Wei, Co-Founder & CEO, and succeed Eric Hall who served as Interim Chief Financial Officer.

Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer

Investors wanted more details from the company's latest clinical results.

Why Connect Biopharma Stock Is Crashing Today

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-307 in adult patients with moderate-to-severe Ulcerative Colitis (UC).

Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis

Connect Biopharma Holdings Limited (NASDAQ: CNTB) has reported topline results from the Phase 2 trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermatitis (AD). The data show that the trial met its primary efficacy endpoint, with statistically significant improvements in the disease severity index score from baseline to Week 16.

Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint

Primary endpoint met with all three CBP-201 arms achieving significant improvements

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis

SAN DIEGO, CA and TAICANG, SUZHOU, China, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, and Dr. Selwyn Ho, Chief Business Officer, will be participating in fireside chats at the following conferences:

Connect Biopharma to Participate at Upcoming Conferences

SAN DIEGO, CA and TAICANG, SUZHOU, China, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO, and Dr. Selwyn Ho, Chief Business Officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, October 26, 2021 at 1:00 pm ET.

Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit

- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

SAN DIEGO and TAICANG, SUZHOU, China, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will report financial results for the first half ended June 30, 2021 after the market closes on Tuesday, August  31, 2021. Connect Biopharma management will host a webcast and conference call to review its results on Wednesday, September 1, 2021, beginning at 8:30 am Eastern Time.

Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021

TAICANG, SUZHOU, China and SAN DIEGO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced Mr. Jiang Bian has joined the Company as General Counsel & Chief Compliance Officer, effective August 20, 2021. In his role, Mr. Bian will oversee Connect Biopharma's legal function and will report to Dr. Zheng Wei, Co-founder and CEO. The hiring of Mr. Bian is an important step in filling out the Company's Executive Leadership and advancing the organizational growth strategy.

Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member

SAN DIEGO and TAICANG, SUZHOU, China, May 26, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & CEO of Connect Biopharma, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 10:00 am ET.

Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference

Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus

Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects

BioNTech SE

Fulgent Genetics

GlaxoSmithKline

Knnate Biopharma

Karyopharm Therapeutics

Legend Biotech

aTyr Pharma

Eli Lilly

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-201 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis

NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Biopharma Holdings Limited (NASDAQ: CNTB), is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell- driven inflammatory diseases with a core expertise in the use of functional cellular assays with T cells to screen discovering potent product candidates aga

Deutsche Bank Appointed as Depositary Bank for the Sponsored American Depositary Receipt Program of Connect Biopharma Holdings Limited

SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T-cell-driven research, today announced the closing of its initial public offering of 12,937,500 American Depositary Shares (“ADSs”), representing 12,937,500 ordinary shares of the Company, at a public offering price of US$17.00 per ADS.

Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares

News for Connect Biopharma Holdings Stock (CNTB)